Keysight Technologies
KEYSIGHT TECHNOLOGIES, INC.
Key figures
Period Nov 2024 to Oct 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$5.4B
Operating marginCalculated
16.3%
Net assets to total assetsCalculated
52.0%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
16.3%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
2.1%
Capital efficiency
★★★☆☆position among all companies
14.5%
Revenue and profit
Performance, financial position and capital allocation
Keysight Technologies
Recent performance trends
Keysight Technologies
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$4.9 billion | US$5.4 billion | US$5.5 billion | US$5.0 billion | US$5.4 billion |
| Operating income | US$1.1 billion | US$1.3 billion | US$1.4 billion | US$0.8 billion | US$0.9 billion |
| Net income | Could not be retrieved | US$1.1 billion | US$1.1 billion | US$0.6 billion | US$0.8 billion |
| Total assets | US$7.8 billion | US$8.1 billion | US$8.7 billion | US$9.3 billion | US$11.3 billion |
| Shareholders' equity | US$3.8 billion | US$4.2 billion | US$4.7 billion | US$5.1 billion | US$5.9 billion |
| Net cash provided by (used in) operating activities | US$1.3 billion | US$1.1 billion | US$1.4 billion | US$1.1 billion | US$1.4 billion |
| Net cash provided by (used in) investing activities | US$-0.4 billion | US$-0.3 billion | US$-0.3 billion | US$-0.8 billion | US$-1.7 billion |
| Net cash provided by (used in) financing activities | US$-0.7 billion | US$-0.9 billion | US$-0.7 billion | US$-0.9 billion | US$0.4 billion |
| Cash and cash equivalents | US$2.1 billion | US$2.0 billion | US$2.5 billion | US$1.8 billion | US$1.9 billion |
Revenue scale in the same industry
Keysight Technologies
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 22 companies
- 26 ResMedFY Jun 2026 US$5.7B
- 27 VeraltoFY Dec 2025 US$5.5B
- 28 Keysight TechnologiesThis companyFY Oct 2025 US$5.4B
- 29 DexcomFY Dec 2025 US$4.7B
- 30 IlluminaFY Dec 2025 US$4.3B
- … 13 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.4 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.1 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$5.9 billion | Consolidated | Disclosed |
| Net assets | US$5.9 billion | Consolidated | Disclosed |
| Net sales | US$5.4 billion | Consolidated | Disclosed |
| Operating income | US$0.9 billion | Consolidated | Disclosed |
| Net income | US$0.8 billion | Consolidated | Disclosed |
| Total assets | US$11.3 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.4 billion | Consolidated | Disclosed |
| Operating margin | 16.3% | Consolidated | Calculated |
| Net assets to total assets | 52.0% | Consolidated | Calculated |
| Net margin | 15.8% | Consolidated | Calculated |
| Return on equity | 14.5% | Consolidated | Calculated |